medigraphic.com

2011, Number 3

<< Back Next >>

Rev Hematol Mex 2011; 12 (3)

Stem cells therapy in neurodegenerative diseases

Moraleda JM, Blanquer M, Gómez-Espuch J, Iniesta F, Hurtado V, Pérez-Espejo MÁ, Rodríguez-Lozano FJ, Martínez S

Language: Spanish
References: 34
Page: 144-148
PDF size: 84.17 Kb.


ABSTRACT

Neurodegenerative diseases are a heterogeneous group of diseases characterized by central nervous system cells death. Unfortunately the majority of them do not have an effective treatment. Although the idea of cell replacement seems a simple and logic therapy, the functional reconstitution of the brain is a difficult task due to the high complexity of the neural circuitry. In animal models of amyotrophic lateral sclerosis, the intraspinal transplant of bone marrow stem cells induces the local increase of neurotrophic factors, delaying motor neuron death. In preclinical studies of Parkinson´s or Alzheimer´s disease the transplant of neural stem cells differentiated to produce the specific deficient neurotransmitter have been achieved. The implanted stem cells might also positively modify the damaged local microenvironment favoring the survival and proliferation of the local stem cells. Preliminary evidence supports the notion that cellular therapy may become a new strategy with the potential to modify the natural course of these deadly diseases. However to date this treatment is still experimental and it is necessary a coordinated effort of basic scientists, clinical investigators, the pharmaceutical industry, and the regulatory agencies, to clarify the unresolved questions about the mechanisms of action, the safety and the efficacy of the stem cells therapy prior to translate it into routine medical practice. These studies must be done following the standards of the stem cell international scientific community.


REFERENCES

  1. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders—how to make it work. Nat Med 2004;10 (suppl): S42-50.

  2. Singec I, Jandial R, Crain A, Nikkhan G, Snyder EY. The leading edge of stem cell therapeutics. Ann Rev Med 2007;58:313-328.

  3. Lopez-Barneo J, Mínguez-Castellanos A, Toledo-Aral JJ, Rodriguez-Gómez JA. Cell therapy for Parkinson´s disease and other CNS disorders. In Cell Therapy, Garcia-Olmo D, Garcia Verdugo JM, Alemany J, Gutierrez Fuentes JA eds. Mc Graw Hill Interamericana. Madrid 2008. pp338-362.

  4. Körbling M, Estrov Z. Adult stem cells for tissue repair ¿a new therapeutic concept? N Engl J Med 2003;349:570-582.

  5. Moraleda JM, Ruiz F, Blanquer M, Arriba F. ¿Que son las células madre? Hematología Mol 2004;3:2-5.

  6. Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci. 2006;7:395-406.

  7. Einstein O, Ben-Hur T. The changing face of neural stem cell therapy in neurological diseases. Arch Neurol 2008;65:452-456.

  8. Shihabuddin LS, Aubert I. Stem cell transplantation for neurometabolic and neurodegenerative diseases. Neuropharmacol 2010;58:845-854.

  9. Madhavan L, Collier T. A synergistic approach for neural repair: Cell transplantation and induction of endogenous precursor cell activity. Neuropharmacol 2010;58:835-844.

  10. Faulkner J, Keirstead HS. Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury. Transpl Immunol 2005;15:131-142.

  11. Yang D, Zhang ZJ, Oldenburg M, Ayala M, Zhang SC. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008;26:55–63.

  12. Kaufman DS. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 2009;114:3513-3523.

  13. Rice células madre, Scolding NJ. Autologous bone marrow stem cells properties and advantages. J Neurol Sciences 2008;265:59-62.

  14. Kucia M, Ratajczak J, Ratajczak MZ. Are bone marrow stem cells plastic or heterogeneous? That is the question. Exp Hematol 2005;33:613-623.

  15. Bonilla S, Alarcon P, Villaverde R, Aparicio P, Silva A, Martinez S. Haematopoietic progenitor cells from adult bone marrow differentiate into cells that express oligodendroglial antigens in the neonatal mouse brain. Eur J Neurosci 2002;15:575-582.

  16. Mezey E, Key S, Vogelsang G, Szalayova I, Lange GD, Crain B. Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci U S A 2003;100:1364-1369.

  17. Bonilla S, Silva A, Valdés L, Geijo E, García-Verdugo JM, Martínez S. Functional neural stem cells derived from adult bone marrow. Neuroscience 2005;133:85-95.

  18. Lu P, Tuszynski MH. Can bone marrow-derived stem cells differentiate into functional neurons? Exp Neurol 2005;193:273-278.

  19. Hedlund E, Hefferan MP, Marsala M, Isacson O. Cell therapy and stem cells in animal models of motor neuron disorders. European J Neuros 2007;26:1721-1737.

  20. Moraleda JM, Blanquer M, Bleda P, Iniesta P, Ruiz F, Bonilla S, Cabanes C, Tabares L, Martinez S. Adult stem cell therapy: Dream or reality? Transplant Immunol 2006;17:74-77.

  21. Cabanes C, Bonilla S, Tabares L, Martínez, S. Neuroprotective effect of adult hematopoietic stem cells in a mouse model of motoneuron degeneration. Neurobiol Dis 2007;26:408-18.

  22. Cerny J, Quesenberry PJ. Chromatin remodeling and the stem cell theory of relativity. J Cell Physiol 2004;201:1-16.

  23. Torrente Y, Polli E. Mesenchymal stem cell transplantation for neurodegenerative diseases. Cell Transplant 2008;17:1103-1113.

  24. Blot S, Poirier C, Dreyfus PA. The mouse mutation muscle deficient (mdf) is characterized by a progressive motoneuron disease. J Neuropathol Exp Neurol 1995;54:812-825.

  25. Blanquer M, Perez Espejo MA, Martinez-Lage JF, Iniesta F, Martinez S, Moraleda JM. A surgical technique of spinal cord cell implantation in amyotrophic lateral sclerosis. J Neurosci Methods 2010;191:255-257.

  26. Blanquer M, Iniesta F, Ruiz FR, Meca J, Gómez Espuch J, Villaverde R, García Santos JM, Torres del Rio S, Funes C, Izura V, de Mingo Casado P, Sánchez Salinas A, Sáez V, Carles R, Antúnez C, Vivancos Moreau L, Hernández Palazón J, Bleda P, Majado MJ, Pérez Espejo MA, Martínez S, Moraleda JM. Phase I-II clinical trial on the use of bone marrow mononuclear cells in the treatment of amyotrophic lateral sclerosis. Ninemonth follow-up. Bone Marrow Transplant 2009;43(Suppl 1):S188.

  27. Blanquer M, Perez Espejo MA, Iniesta F Gomez Espuch J, Meca J, Villaverde R, Izura V, de Mingo P, Martinez-Lage J, Martinez S, Moraleda JM. Bone marrow stem cell transplantation in amyotrophic lateral sclerosis: technical aspects and preliminary results from a clinical trial. Methods Find Exp Clin Pharmacol 2010;32(Suppl A):31-3.

  28. Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res. 2009;87:2183-2200.

  29. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131(5):861-872.

  30. Koch P, Kokaia Z, Lindvall O, Brustle O. Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling. Lancet Neurol 2009;8:819-29.

  31. Orive G, Anitua E, Pedraz JL, Emerich DF. Biomaterials for promoting brain protection, repair and regeneration. Nat Rev Neurosci 2009;10:682-692.

  32. Hyun I, Lindvall O, Ahrlund-Richter L, Cattaneo E, et al. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell. 2008;3:607-609.

  33. Lindvall O , Hyun I. Medical innovation versus stem cell tourism. Science 2009;324: 1664–1665.

  34. Master Z, Resnik DB. Stem-cell tourism and scientific responsibility. EMBO reports advance online publication 29 July 2011; doi:10.1038/embor.2011.156.




2020     |     www.medigraphic.com